search
Back to results

Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics

Primary Purpose

Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Continuous Glucose Monitoring
Sponsored by
Medtronic Diabetes
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Type 1 Diabetes Mellitus

Eligibility Criteria

2 Years - 80 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Individual is 2 - 80 years of age at time of enrollment.
  2. Subject has a clinical diagnosis of type 1 or type 2 diabetes:

    1. If subject is 14-80 years of age, subject has a clinical diagnosis of type 1 or type 2 diabetes for a minimum of 6 months duration as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis.
    2. If subject is 2-13 years of age, subject has a clinical diagnosis of type 1 or type 2 diabetes as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis.
  3. If subject is participating in YSI™* FST , subject has adequate venous access as assessed by investigator or appropriate staff.
  4. Subjects participating in the high and low glucose challenges must have an insulin carbohydrate ratio(s) and insulin sensitivity factor(s). Subjects without ratios may participate under observation only.

Exclusion Criteria:

  1. Subject will not tolerate tape adhesive in the area of sensor placement as assessed by a qualified individual.
  2. Subject has any unresolved adverse skin condition in the area of sensor or device placement (e.g., psoriasis, rash, Staphylococcus infection).
  3. Subject is actively participating in an investigational study (e.g., drug or device) wherein he/she has received treatment from an investigational study (drug or device) in the last 2 weeks prior to Visit 1. (Please note participation in an observational study is acceptable.)
  4. Subject is female of child-bearing potential and has a pregnancy screening test that is positive.
  5. Subject is a sexually active female of child-bearing potential and is not using a form of contraception deemed reliable by investigator.
  6. Subject is female and plans to become pregnant during the course of the study.
  7. Subject has had a hypoglycemic seizure within the past 6 months prior to enrollment.
  8. Subject has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to enrollment.
  9. Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months prior to enrollment.
  10. Subject has a history of a seizure disorder.
  11. Subject has central nervous system or cardiac disorder resulting in syncope.
  12. Subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (TIA), cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease
  13. If subject is 7-80 years of age, subject has a hematocrit (Hct) more than 10% below the lower limit of normal reference range (please note that patients may use prior blood draw from routine care as long as done within 6 months of screening and report of lab placed with subject source documents).
  14. Subject has a history of adrenal insufficiency.
  15. Subject is a member of the research staff involved with the study.

Sites / Locations

  • AMCR Institute
  • Sansum Diabetes Research Institute
  • SoCal Diabetes
  • Diablo Clinical Research, Inc.
  • Barbara Davis Center for Childhood Diabetes
  • Barbara Davis Center for Diabetes
  • University of South Florida
  • Atlanta Diabetes Associates
  • Rocky Mountain Diabetes and Osteoporosis Center
  • AM Diabetes and Endocrinology Center
  • Texas Diabetes & Endocrinology
  • University of Virginia Center for Diabetes Technology
  • Rainier Clinical Research Center, Inc.
  • Nanjing First Hospital
  • Dalian Municiple Central Hospital
  • Shanghai Sixth People's Hospital
  • Children's Hospital of Fudan University
  • The Children's Hospital Zhejiang University School of Medicine

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Subjects with diabetes wearing DS5

Arm Description

Subjects wearing DS5 over 7 days and participating in FSTs.

Outcomes

Primary Outcome Measures

Percentage of Readings Within 20% Agreement
Mean of daily percentage of sensor values within 20% of Yellow Springs Instrument (YSI™*) reference value (within 20 mg/dL [1.1 mmol/L] when sensor values < 80 mg/dL) [4.4 mmol/L]) by age groups and DS5 insertion locations. Note Self-Monitoring Blood Glucose (SMBG) was used for age 2-6, instead of YSI. Zero calibration sensor algorithm applied to raw sensor data.

Secondary Outcome Measures

Full Information

First Posted
June 12, 2020
Last Updated
May 4, 2023
Sponsor
Medtronic Diabetes
search

1. Study Identification

Unique Protocol Identification Number
NCT04436822
Brief Title
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
Official Title
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
July 15, 2020 (Actual)
Primary Completion Date
April 12, 2022 (Actual)
Study Completion Date
April 12, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic Diabetes

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes

5. Study Description

Brief Summary
The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).
Detailed Description
The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days). This is a multi-center study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
317 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Subjects with diabetes wearing DS5
Arm Type
Experimental
Arm Description
Subjects wearing DS5 over 7 days and participating in FSTs.
Intervention Type
Device
Intervention Name(s)
Continuous Glucose Monitoring
Intervention Description
CGM and frequent sample testing
Primary Outcome Measure Information:
Title
Percentage of Readings Within 20% Agreement
Description
Mean of daily percentage of sensor values within 20% of Yellow Springs Instrument (YSI™*) reference value (within 20 mg/dL [1.1 mmol/L] when sensor values < 80 mg/dL) [4.4 mmol/L]) by age groups and DS5 insertion locations. Note Self-Monitoring Blood Glucose (SMBG) was used for age 2-6, instead of YSI. Zero calibration sensor algorithm applied to raw sensor data.
Time Frame
7 days (170 hours)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Individual is 2 - 80 years of age at time of enrollment. Subject has a clinical diagnosis of type 1 or type 2 diabetes: If subject is 14-80 years of age, subject has a clinical diagnosis of type 1 or type 2 diabetes for a minimum of 6 months duration as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis. If subject is 2-13 years of age, subject has a clinical diagnosis of type 1 or type 2 diabetes as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis. If subject is participating in YSI™* FST , subject has adequate venous access as assessed by investigator or appropriate staff. Subjects participating in the high and low glucose challenges must have an insulin carbohydrate ratio(s) and insulin sensitivity factor(s). Subjects without ratios may participate under observation only. Exclusion Criteria: Subject will not tolerate tape adhesive in the area of sensor placement as assessed by a qualified individual. Subject has any unresolved adverse skin condition in the area of sensor or device placement (e.g., psoriasis, rash, Staphylococcus infection). Subject is actively participating in an investigational study (e.g., drug or device) wherein he/she has received treatment from an investigational study (drug or device) in the last 2 weeks prior to Visit 1. (Please note participation in an observational study is acceptable.) Subject is female of child-bearing potential and has a pregnancy screening test that is positive. Subject is a sexually active female of child-bearing potential and is not using a form of contraception deemed reliable by investigator. Subject is female and plans to become pregnant during the course of the study. Subject has had a hypoglycemic seizure within the past 6 months prior to enrollment. Subject has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to enrollment. Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months prior to enrollment. Subject has a history of a seizure disorder. Subject has central nervous system or cardiac disorder resulting in syncope. Subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (TIA), cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease If subject is 7-80 years of age, subject has a hematocrit (Hct) more than 10% below the lower limit of normal reference range (please note that patients may use prior blood draw from routine care as long as done within 6 months of screening and report of lab placed with subject source documents). Subject has a history of adrenal insufficiency. Subject is a member of the research staff involved with the study.
Facility Information:
Facility Name
AMCR Institute
City
Escondido
State/Province
California
ZIP/Postal Code
92025
Country
United States
Facility Name
Sansum Diabetes Research Institute
City
Santa Barbara
State/Province
California
ZIP/Postal Code
93105
Country
United States
Facility Name
SoCal Diabetes
City
Torrance
State/Province
California
ZIP/Postal Code
90505
Country
United States
Facility Name
Diablo Clinical Research, Inc.
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94598
Country
United States
Facility Name
Barbara Davis Center for Childhood Diabetes
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
Barbara Davis Center for Diabetes
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
University of South Florida
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Facility Name
Atlanta Diabetes Associates
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30318
Country
United States
Facility Name
Rocky Mountain Diabetes and Osteoporosis Center
City
Idaho Falls
State/Province
Idaho
ZIP/Postal Code
83404
Country
United States
Facility Name
AM Diabetes and Endocrinology Center
City
Bartlett
State/Province
Tennessee
ZIP/Postal Code
38133
Country
United States
Facility Name
Texas Diabetes & Endocrinology
City
Austin
State/Province
Texas
ZIP/Postal Code
78749
Country
United States
Facility Name
University of Virginia Center for Diabetes Technology
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22903
Country
United States
Facility Name
Rainier Clinical Research Center, Inc.
City
Renton
State/Province
Washington
ZIP/Postal Code
98057
Country
United States
Facility Name
Nanjing First Hospital
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210008
Country
China
Facility Name
Dalian Municiple Central Hospital
City
Dalian
State/Province
Liaoning
ZIP/Postal Code
116089
Country
China
Facility Name
Shanghai Sixth People's Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200233
Country
China
Facility Name
Children's Hospital of Fudan University
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
201102
Country
China
Facility Name
The Children's Hospital Zhejiang University School of Medicine
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310005
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics

We'll reach out to this number within 24 hrs